We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

BioVendor Group

BioVendor Group is an international group of biotechnology companies (BioVendor LM, BioVendor R&D, TestLine, ViennaLa... read more Featured Products: More products

Download Mobile App





BioVendor Group Demonstrates Unique IVD Platform and Immunoblot Test

By LabMedica International staff writers
Posted on 15 Nov 2023

BioVendor Group (Brno, Czech Republic) is demonstrating its IVD solutions in the form of a CLIA platform, a new generation of a unique immunoblot test for effective multiplex diagnostics, Microblot-Array, or its comprehensive sequencing solution using the NGS method at MEDICA 2023. More...

MEDICA is the world's largest medical trade fair of all - with several thousand exhibitors from more than 60 nations in the exhibition halls. A wide range of innovative products and services from the fields of medical imaging, laboratory technology, diagnostics, health IT, mobile health as well as physiotherapy/orthopedic technology and medical consumables are being presented here.

At this year’s MEDICA, BioVendor is demonstrating the KleeYa fully automated analyzer which is versatile, fast, smooth, and intuitive, working like a perfectly coordinated orchestra. The operator is only required to set, run, and exit with KleeYa taking care of the rest and operating independently for a long time, thanks to the high-capacity consumable containers. With a graphical user interface, the operator can learn to control the fully automated system in minutes. Additionally, KleeYa software is designed to minimize the burden on laboratory staff. BioVendor is also highlighting Microblot–Array (MBA), a new generation of unique, immunoblot arrays in a microtiter plate format. It is designed for efficient multiplex diagnostics, enabling the simultaneous detection of multiple markers which can save time and lower costs. The technology eliminates the limited capacity of traditional BLOT strips and opens the opportunity for high throughput testing.

Processing can be performed automatically using open ELISA analyzers. The evaluation is performed by the Microblot–Array Reader and software (SW). Results can be exported in various formats and the system can be connected to LIS. In addition, BioVendor is showcasing its new fastGEN technology for the examination of the mutation status of oncomarkers in samples. The technology is based on ultra-deep sequencing of short amplicons obtained by a single polymerase chain reaction with specially tagged hybrid primers. The fastGEN technology is simple, ultra-sensitive, specific, and effective - it is perfectly adapted to diagnostics and offers new advantages for clinical material.

Related Links:
BioVendor Group 


New
Gold Member
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Online QC Software
Acusera 24•7
All-in-One Molecular System
AIO M160
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The approach supports myocardial infarction diagnosis in resource-limited settings by reducing delays between clinical suspicion and biochemical confirmation (Image Credit: Adobe Stock)

Portable Troponin Assay Brings Heart Attack Diagnosis Closer to Patients

Timely confirmation of myocardial infarction often depends on laboratory testing that may not be immediately available at the point of care. This gap between clinical suspicion and definitive evidence... Read more

Molecular Diagnostics

view channel
Image: The platform analyzes cell-free DNA in blood, searching for minute amounts of tumor-derived fragments among background DNA (Image Credit: Adobe Stock)

Blood Test Could Help Fast-Track Lymphoma Diagnosis in Resource-Limited Settings

Lymphoma can be difficult to distinguish from infections and benign conditions, while definitive diagnosis often depends on surgical tissue sampling and specialized pathology that may not be readily available.... Read more

Microbiology

view channel
Image: An innovative countywide program in Taiwan combines risk-based screening with decentralized community care to improve hepatitis C detection and treatment (Image Credit: iStock)

Precision Screening Helps Close Hepatitis C Diagnosis and Treatment Gaps

Hepatitis C remains a leading cause of cirrhosis and liver cancer, yet many infections go undiagnosed or untreated because health systems fail to reach those at greatest risk. Although highly effective... Read more

Pathology

view channel
Image: Through the PCCP, Proscia gains a more efficient pathway to expand Concentriq AP-Dx interoperability while maintaining regulatory oversight (Photo courtesy of Proscia)

FDA-Cleared Digital Pathology Platform Expands Interoperability for Primary Diagnosis

Rising cancer incidence is colliding with a shrinking pathologist workforce, intensifying pressure on diagnostic turnaround times in clinical laboratories. Many labs are adopting digital pathology to manage... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.